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The objective of this retrospective study is to evaluate the prevalence of
KRAS mutation in canine gastrointestinal tumors, through the study of
KRAS expression in conserved tissue samples. A further aim, is to study the
influence of other factors, such as stage and treatment, on survival time.
METHODS
• Criteria for Case Inclusion: tissue simple, minimal clinic record and 
staging of the tumor (human TNM criteria)
• DNA extraction and KRAS gene analysis: cell lysis (EZ1 DNA Tissue kit, 
QUIAGEN), DNA fragment measurement, KRAS determination 
(Therascreen KRAS RGQ PCR) with real-time PCR cycler (QUIAGEN)




1. The incidence of the KRAS mutation in dog gastrointestinal tumors couldn’t
be defined in this study.
2. There are differences in the survival mean time depending on treatment and
stage of the tumor but they are not statistically significant according to Log
Rank and Chi sqaured test results.
3. The lack of follow up in a high percentage of the cases, and the small size of
the simple (N) may have influenced the survival results
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Incidence and mortality of most commonly diagnosed 
cancer types worldwide (WHO, 2012)
Incidence Mortality
Colorectal and stomach cancer, affect 2.312.196 people and cause 
1.417.006 deaths annually. 95% of these tumors are adenocarcinomas. 
EFGR play a crucial role in tumorigenesis due to its function in cell signaling
pathway. Therefore, current medical therapies in humans are based on the
use of EFGR inhibitors.
A lack of response in some tumors to targeted therapy has led to the study
of predictive biomarkers such as KRAS. This oncogene also plays a role in cell
signaling and so, mutations may cause an upregulation of the cell cycle
enhancing proliferation, migration, angiogenesis and evasion of apoptotic
signals. About 40% of gastrointestinal human tumors carry the mutated





Chemotherapy NSAIDs No treatment
28 dogs were included in the database, all of them diagnosed with any solid
gastrointestinal tumor. The mean age at diagnostic was 9’3 years old, with
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Group Mean Median Censored
Total 12,1 5,5 14 (50%)
Treatment
No treatment 11,7 4,5 8 (57,1%)
Chemotherapy 11,25 7 2 (25%)
NSAIDs 14,7 16,5 4 (66,7%)
Stage
I 13,2 9,5 9 (60%)
>I 11,2 5 5 (38,5%)
Global survival mean time
Survival mean time per 
treatment (None (0)/Ch-
NSAIDs (1))
Survival mean time per stage
Survival mean time per 
treatment (None (0)/ 
Ch (1)/NSAIDs (2))
There are differences among
stage and treatment groups,
but according to Chi square
test, they are not statistically
significant.
